Quick Answer
Inhibrx Biosciences, Inc. reported Net Income of -$140.06 million for fiscal year 2025.
Inhibrx Biosciences, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$140.06M | -108.3% |
| 2024 | $1.69B | +799.2% |
| 2023 | -$241.36M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$35.26M | +19.6% | -23.0% |
| June 30, 2025 | -$28.65M | -101.5% | +33.8% |
| March 31, 2025 | -$43.31M | +45.0% | +1.3% |
| September 30, 2024 | -$43.86M | +15.3% | -102.4% |
| June 30, 2024 | $1.86B | +4048.8% | +2460.6% |
| March 31, 2024 | -$78.71M | -60.9% | -52.0% |
| September 30, 2023 | -$51.79M | — | -10.1% |
| June 30, 2023 | -$47.05M | — | +3.8% |
- Inhibrx Biosciences, Inc. showed a decrease of -108.3% in Net Income compared to the prior fiscal year.
- Over the 2023–2025 period, Inhibrx Biosciences, Inc.’s net income has grown by 42.0% (from -$241.36 million to -$140.06 million).
- The most recent figure is from Inhibrx Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: